BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/26/2025 7:56:33 AM | Browse: 4 | Download: 16
 |
Received |
|
2025-04-10 01:48 |
|
Peer-Review Started |
|
2025-04-10 01:48 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-05-07 02:35 |
|
Revised |
|
2025-05-08 17:26 |
|
Second Decision |
|
2025-06-11 02:41 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-06-11 07:14 |
|
Articles in Press |
|
2025-06-11 07:14 |
|
Publication Fee Transferred |
|
2025-05-09 17:11 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-06-24 00:42 |
|
Publish the Manuscript Online |
|
2025-06-26 07:56 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhao Gao, Xiao-Yan Wang, Zhi-Gang Shen, Jia-Hua Liu, Xiao-Yun Wang, Shi-Kai Wu and Xuan Jin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National High Level Hospital Clinical Research Funding (Multi-Center Clinical Research Project of Peking University First Hospital) |
No. 2022CR65 |
|
| Corresponding Author |
Xuan Jin, Chief Physician, PhD, Department of Medical Oncology, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, China. 27051079@qq.com |
| Key Words |
Microsatellite stable; RAS mutation; Metastatic colorectal cancer; Immune checkpoint inhibitors; Programmed death 1 |
| Core Tip |
Patients with microsatellite stable metastatic colorectal cancer typically exhibit an immunosuppressive tumor microenvironment and demonstrate a low response rate to immunotherapy. Clinical trial data suggest that chemotherapy and anti-angiogenic therapy may have the potential to enhance the response to immunotherapy in these patients. However, whether these research findings can be “replicated” in clinical practice still requires further validation through real-world studies. This study aims to evaluate the effectiveness and safety of chemotherapy combined with bevacizumab with or without anti-programmed death 1 immunotherapy as the first-line regimen for microsatellite stable metastatic colorectal cancer in the real world. |
| Publish Date |
2025-06-26 07:56 |
| Citation |
<p>Gao Z, Wang XY, Shen ZG, Liu JH, Wang XY, Wu SK, Jin X. Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer. <i>World J Gastroenterol</i> 2025; 31(24): 108298</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i24/108298.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i24.108298 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
